✉news BusinessRetail first seen 1 d ago, last 1 d ago, peak #17
SLS Stock Falls on AML Trial Milestone Despite Bullish Retail Bets
Original: SLS Stock’s Big AML Trial Milestone Sparks A Selloff — What’s Fueling Retail’s ‘Extremely Bullish’ Bets?
Shares of SLS sold off after the company reached a significant milestone in its acute myeloid leukemia (AML) trial, an outcome investors might normally welcome. Retail traders, however, are described as 'extremely bullish' on the stock, buying the dip and betting on the therapy's prospects. The split between an institutional selloff and enthusiastic retail accumulation is drawing attention across trading forums and finance outlets.
Why now: The contrast between a share-price selloff on the trial news and strongly bullish retail positioning is fueling debate about the stock's direction.
Rank over time, top of the chart is #1. 5 snapshots from 1 d ago to 1 d ago.
Evidence
- SLS Stock’s Big AML Trial Milestone Sparks A Selloff — What’s Fueling Retail’s ‘Extremely Bullish’ Bets? · Yahoo Finance
- SLS Stock’s Big AML Trial Milestone Sparks A Selloff — What’s Fueling Retail’s ‘Extremely Bullish’ Bets? · Stocktwits
API: https://socialmediatrends-api.osmike.com/v1/trends/4070661